Physician
Jim C. Kim, M.D., INC
Jim C. Kim, M.D., INC was paid $4.09M by Medicaid between Jan 2018 and Nov 2024, across 17 billing codes. Its largest line is J0129, Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) — 75% of everything it billed.
33Billing provider infoJIM C. KIM, M.D., INC
BAKERSFIELD, CA 93301
BAKERSFIELD, CA 93301
33aNPI1841352663assigned 12/15/2006
33bProvider typeRheumatology Physician
28Total paid$4.09M
24GClaims18,722
24DCodes billed17
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Rheumatology Physician providers in California
Rank by total paid#10 of 147
Median peer was paid$43K
This provider vs. median94×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 225 | $1K | |
| 2019 | 994 | $183K | |
| 2020 | 3,700 | $952K | |
| 2021 | 3,876 | $1.06M | |
| 2022 | 3,687 | $904K | |
| 2023 | 3,662 | $632K | |
| 2024incomplete | 2,578 | $355K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 75% | 1,644 | 1,559 | $3.06M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.3% | 4,102 | 3,954 | $298K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.1% | 5,549 | 5,400 | $292K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 4.1% | 1,480 | 1,420 | $166K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.1% | 1,650 | 1,549 | $127K |
| J7050 | Infusion, normal saline solution, 250 cc | 1.5% | 2,828 | 2,672 | $60K |
| J3262 | Injection, tocilizumab, 1 mg | <1% | 20 | 12 | $36K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | <1% | 411 | 410 | $31K |
| 99243 | <1% | 221 | 221 | $16K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 254 | 240 | $2K |
| 99442 | <1% | 53 | 52 | $1K | |
| 96415 | <1% | 65 | 64 | $1K |
5 more codes
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 140 | $479.81 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 205 | $318.58 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 31 | $196.47 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 14 | $104.16 |
| 99441 | 0% | 55 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKIM, JIM (PRESIDENT)